thalidomide has been researched along with Asthenia in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Asthenia: Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination." | 9.12 | A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 7.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| " The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time." | 5.37 | Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. ( García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E, 2011) |
| "This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination." | 5.12 | A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 3.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| " The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time." | 1.37 | Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. ( García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E, 2011) |
| "Asthenia is the most common adverse effect of treatment, occurring in approximately 76% to 96% of patients receiving therapy." | 1.36 | Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. ( Anderson, K; Laubach, JP; Mitsiades, C; Richardson, PG; Schlossman, RL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Richardson, PG | 1 |
| Laubach, JP | 1 |
| Schlossman, RL | 1 |
| Mitsiades, C | 1 |
| Anderson, K | 1 |
| Pérez Persona, E | 1 |
| Mesa, MG | 1 |
| García Sánchez, PJ | 1 |
| González Rodríguez, AP | 1 |
| del Giglio, A | 1 |
| Weinschenker, P | 1 |
| Manhani, AR | 1 |
| Carbonell, AL | 1 |
| Mitteldorf, CA | 1 |
| Mita, MM | 1 |
| Rowinsky, EK | 1 |
| Forero, L | 1 |
| Eckhart, SG | 1 |
| Izbicka, E | 1 |
| Weiss, GR | 1 |
| Beeram, M | 1 |
| Mita, AC | 1 |
| de Bono, JS | 1 |
| Tolcher, AW | 1 |
| Hammond, LA | 1 |
| Simmons, P | 1 |
| Berg, K | 1 |
| Takimoto, C | 1 |
| Patnaik, A | 1 |
| Vaishampayan, UN | 1 |
| Heilbrun, LK | 1 |
| Shields, AF | 1 |
| Lawhorn-Crews, J | 1 |
| Baranowski, K | 1 |
| Smith, D | 1 |
| Flaherty, LE | 1 |
2 trials available for thalidomide and Asthenia
| Article | Year |
|---|---|
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Asthenia; Dose-Response Relationship, Drug; | 2007 |
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcino | 2007 |
3 other studies available for thalidomide and Asthenia
| Article | Year |
|---|---|
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Humans; Multipl | 2010 |
Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.
Topics: Adrenal Insufficiency; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2011 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Human | 2005 |